• SPX
  • $5,740.20
  • 0.48 %
  • $27.51
  • DJI
  • $41,959.49
  • 0.39 %
  • $164.88
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,159.91
  • -0.3 %
  • -$24.33
  • IXIC
  • $18,313.33
  • 0.73 %
  • $133.35
Homology Medicines, Inc. (FIXX) Stock Price, News & Analysis

Homology Medicines, Inc. (FIXX) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$0.9
Day's range
$0.97
50-day range
$0.9
Day's range
$17.28
  • Country: US
  • ISIN: US4380831077
52 wk range
$0.9
Day's range
$26.64
  • CEO: Dr. Paul Alloway J.D., Ph.D.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.71
  • Piotroski Score 1.00
  • Grade Neutral
  • Symbol (FIXX)
  • Company Homology Medicines, Inc.
  • Price $0.93
  • Changes Percentage (0.77%)
  • Change $0.01
  • Day Low $0.90
  • Day High $0.97
  • Year High $26.64

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 05/08/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $2.70
  • High Stock Price Target $2.70
  • Low Stock Price Target $2.70
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$35.10
  • Trailing P/E Ratio -0.02662962962963
  • Forward P/E Ratio -0.02662962962963
  • P/E Growth -0.02662962962963
  • Net Income $-112,961,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.